- Home
- Publications
- Publication Search
- Publication Details
Title
Combination immunotherapy for hepatocellular carcinoma
Authors
Keywords
-
Journal
JOURNAL OF HEPATOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-03-17
DOI
10.1016/j.jhep.2023.03.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
- (2022) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
- (2022) Roger Esteban-Fabró et al. CLINICAL CANCER RESEARCH
- Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
- (2022) Andrew X. Zhu et al. CLINICAL CANCER RESEARCH
- Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
- (2022) Antonio D’Alessio et al. HEPATOLOGY
- Hepatocellular Carcinoma: Pick the Winner—Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent–Based Combinations
- (2022) Anthony C. Bejjani et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
- (2022) Ahmed Omar Kaseb et al. Lancet Gastroenterology & Hepatology
- Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
- (2022) Thomas U Marron et al. Lancet Gastroenterology & Hepatology
- Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial.
- (2022) Antonio D'Alessio et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
- (2022) Robin Kate Kelley et al. LANCET ONCOLOGY
- Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
- (2022) Andrew X. Zhu et al. NATURE MEDICINE
- Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Gastroenterology & Hepatology
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- Advances in immunotherapy for hepatocellular carcinoma
- (2021) Bruno Sangro et al. Nature Reviews Gastroenterology & Hepatology
- Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
- (2021) Zhe Fu et al. Cells
- Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)
- (2021) Philipp K. Haber et al. GASTROENTEROLOGY
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
- (2021) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
- (2021) Masatoshi Kudo et al. JOURNAL OF HEPATOLOGY
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
- (2021) Zhenggang Ren et al. LANCET ONCOLOGY
- Hepatocellular Carcinoma — Origins and Outcomes
- (2021) Robin K. Kelley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
- (2021) David J. Pinato et al. EUROPEAN JOURNAL OF CANCER
- Systemic treatment of hepatocellular carcinoma: An EASL position paper
- (2021) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
- (2021) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
- (2021) Thomas Yau et al. LANCET ONCOLOGY
- Radiomics in hepatocellular carcinoma: A state-of-the-art review
- (2021) Shan Yao et al. World Journal of Gastrointestinal Oncology
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deep Learning Radiomics Based on Contrast-Enhanced Ultrasound Might Optimize Curative Treatments for Very-Early or Early-Stage Hepatocellular Carcinoma Patients
- (2020) Fei Liu et al. Liver Cancer
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non-randomized, open-label, phase 2 trial
- (2020) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
- (2020) Chang Gon Kim et al. JOURNAL OF HEPATOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Systemic treatment of HCC in special populations
- (2020) Lorenza Rimassa et al. JOURNAL OF HEPATOLOGY
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
- (2019) Rui-Yan Wu et al. CLINICAL CANCER RESEARCH
- Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy
- (2019) Carina Hage et al. PLoS One
- Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
- (2019) Yi Zheng et al. Journal for ImmunoTherapy of Cancer
- Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
- (2019) Spencer C. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells
- (2018) Meng-jun Qiu et al. CLINICA CHIMICA ACTA
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study
- (2018) David J. Pinato et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- The epigenetic landscape of T cell exhaustion
- (2016) D. R. Sen et al. SCIENCE
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancer and the Immune System: Basic Concepts and Targets for Intervention
- (2015) Drew Pardoll SEMINARS IN ONCOLOGY
- Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment
- (2014) Hui-Yen Chuang et al. PLoS One
- Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells
- (2013) Martin Franz Sprinzl et al. HEPATOLOGY
- Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
- (2013) Mei-Ling Chen et al. INTERNATIONAL JOURNAL OF CANCER
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Antiangiogenic Therapies for Advanced Hepatocellular Carcinoma
- (2013) K. R. Sampat et al. ONCOLOGIST
- VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
- (2012) N G Gavalas et al. BRITISH JOURNAL OF CANCER
- Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma
- (2012) Roniel Cabrera et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
- (2011) Mengde Cao et al. LABORATORY INVESTIGATION
- The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages
- (2010) Justin P. Edwards et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
- (2009) C. L. Roland et al. MOLECULAR CANCER THERAPEUTICS
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started